CARsgen Therapeutics Holdings Ltd. has announced positive clinical data for its allogeneic CAR-T product candidates CT0596 and CT1190B. CT0596, which targets BCMA, is being evaluated for relapsed/refractory multiple myeloma (R/R MM) and has entered the dose expansion phase in an investigator-initiated trial (NCT06718270). Among the eight patients infused as of June 24, 2025, five achieved a partial response or better, including three who achieved complete or stringent complete responses. Six patients achieved minimal residual disease negativity at Week 4, and no dose-limiting toxicities, treatment discontinuations, or deaths were observed. CT1190B, a CD19/CD20-targeted allogeneic CAR-T cell therapy candidate, is being studied in ongoing investigator-initiated trials (NCT07053670, NCT06734871) for relapsed/refractory non-Hodgkin's lymphoma (R/R NHL). As of October 17, 2025, 14 patients had been enrolled, and the dose escalation study has been completed with preliminary identification of the recommended lymphodepletion regimen and cell dose. The company previously presented preliminary data for CT0596 in relapsed/refractory primary plasma cell leukemia (pPCL) in October 2025, where two heavily pretreated patients achieved stringent complete responses.